Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Non-Current Debt (2018 - 2025)

Abeona Therapeutics (ABEO) has 7 years of Non-Current Debt data on record, last reported at $10.9 million in Q3 2025.

  • For Q3 2025, Non-Current Debt fell 23.54% year-over-year to $10.9 million; the TTM value through Sep 2025 reached $10.9 million, down 23.54%, while the annual FY2024 figure was $13.0 million, N/A changed from the prior year.
  • Non-Current Debt reached $10.9 million in Q3 2025 per ABEO's latest filing, down from $14.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $18.1 million in Q1 2024 and bottomed at $1.2 million in Q1 2021.
  • Average Non-Current Debt over 4 years is $9.1 million, with a median of $9.6 million recorded in 2021.
  • The widest YoY moves for Non-Current Debt: up 224.15% in 2022, down 51.39% in 2022.
  • A 4-year view of Non-Current Debt shows it stood at $3.8 million in 2021, then increased by 8.75% to $4.2 million in 2022, then skyrocketed by 213.16% to $13.0 million in 2024, then decreased by 16.68% to $10.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $10.9 million in Q3 2025, $14.0 million in Q2 2025, and $11.1 million in Q1 2025.